The research and development of PARP inhibitors for the treatment of BRCA1/2 mutations is on the verge of white heat

Recently, due to the prominent performance of PARP inhibitors in the treatment of breast and ovarian cancer, the research and development of PARP inhibitors for BRCA1/2 mutations and the fierce market competition have rapidly increased, which has aroused the interest of many drug developers. At the time, it is necessary to make a discussion on the context of the rapid change of PARP inhibitors into "fire", which may also give us some inspiration when grasping the market.Angelina Jolie and the BRCA1/2 mutation
are not the same as other cancer gene mutations, BRCA1/2 mutations into the public eye and "famous" can be said to be with Hollywood actress Angelina. Julie (later referred to as Julie) doesn't matter. Back in 2013, Jolie published an article in the New York Times titled "My Medical Choices," in which she said she carried the BRCA1 gene and underwent a preventive double mastectomy to reduce her risk of cancer.
Julie's mother battled cancer for nearly a decade, but died at the age of 56. Genetic testing suggests that Julie inherited her mother's mutant BRCA1 gene, resulting in an 87% and 50% risk of breast and ovarian cancer, respectively. As a result, Julie underwent a mastectomy from the breast cancer with the highest risk. In 2015, Jolie underwent further surgery to remove her ovaries and fallopian tubes to reduce her risk of cancer. Julie points out that her experience is made public in order to draw attention to specific types of breast and ovarian cancer, especially those associated with BRCA1 gene mutations. Facts have also proved that the BRCA1/2 mutation has now attracted more and more attention and attention.about BRCA1/2
BRCA1/2 are two cancer-suppressing genes. In 1990, researchers discovered a gene associated with breast cancer and named it Breast Cancer 1, or BRCA1, because it was associated with breast cancer; In fact, BRCA1/2, as a cancer-suppressing gene, plays an important role in regulating cell replication, DNA damage repair, and normal cell growth.
when the BRCA1/2 gene mutates, its anti-cancer effect disappears and the risk of cancer increases dramatically. Statistics show that the risk of breast and ovarian cancer in BRCA1 mutants is 50%-85%, 15%-45%, and in BRCA2 gene mutants, the risk of breast cancer and ovarian cancer in BRCA1 mutants is 50%-85% and 10%-20%, respectively. In other words, people with BRCA1/2 gene mutations are significantly more likely to develop cancer than the average woman.The birth and development of PARP inhibitors
Since the BRCA1/2 gene mutation is closely related to the occurrence of cancer diseases such as breast cancer and ovarian cancer, the BRCA1/2 mutation gene has naturally become an important target for these cancer treatments, so PARP inhibitors for BRCA1/2 mutations should be born from time to time.
PARP is a polyADP icingase, which is closely related to the process of cell chromosomal remodeling, apoptosis and division. In 2005, researchers first confirmed that BRCA1/2 mutations play an important role in PARP inhibitor sensitivity. Since then, researchers appear to have found a breakthrough in BRCA1/2 mutation therapy, and many drug development agencies have quickly initiated the development of PARP inhibitors.approved parp inhibitors
In 2014, AstraZeneatic's olaparib successfully went on sale, becoming the first FDA-approved PARP inhibitor to be used primarily for the treatment of breast and ovarian cancer. Pfizer's Rucaparib and Merck's Niraparib were subsequently approved by the FDA in 2016 and 2017, respectively. It is worth mentioning that Merck's niraparib successfully listed in Hong Kong, China, making Hong Kong, China, the third place after the United States and the European Union to approve the listing of niraparib.
PARP inhibitors, which are currently approved for sale, are listed this year with FDA approval, in addition to the three drugs on the market. In addition, AbbVie, Baiji Shenzhou and other pharmaceutical companies have corresponding products in the clinical research stage. From the point of view of adaptation, PARP inhibitors are mainly targeted at breast cancer, ovarian cancer, but also fallopian tube cancer, peritina cancer, prostate cancer and stomach cancer.conclusion
from the above analysis, it can be seen that the BRCA1/2 mutation and its treatment drug PARP inhibitors from discovery to change "fire", not overnight. But since the successful launch of the first PARP inhibitors, such targeted drugs have attracted increasing attention, and more recently! As PARP inhibitor research continues, there will be better PARP inhibitors on the market in the future, bringing more good news to cancer patients such as breast cancer. (Bio Valley)